1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BioNotebook: Second Genome/Pfizer, Merck/Agenus, Endo/Somar, Parion/Gilead, Lightstone Ventures, Kite Pharma, five IPO updates

 
• By Mandy Jackson

Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.

Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.

Second Genome, Pfizer search microbiome for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.